Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Buti

Showing results (951-960 of 1,095) with videos related to

Pageof 110
Sort By:
JHEP Reports : Innovation in Hepatology|July 24, 2023
Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: A multicentre cohort studyMilan J Sonneveld, Shao-Ming Chiu, Jun Yong Park, et al.
Journal of Hepatology|December 31, 2017
Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis CJavier Ampuero, Carlota Jimeno, Rosa Quiles, et al.
Cancer Immunology, Immunotherapy : CII|June 4, 2024
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinationsLorena Incorvaia, Fernando Sabino Marques Monteiro, Francesco Massari, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 10, 2011
A systematic review of hepatitis C virus epidemiology in Europe, Canada and IsraelMarkus Cornberg, Homie A Razavi, Alfredo Alberti, et al.
Clinical & Experimental Metastasis|November 21, 2025
Time to metastasis as a prognostic factor in metastatic urothelial carcinoma: results from the ARON-2 studyRenate Pichler, Gerald Klinglmair, Kirstin Binz, et al.
Gastroenterology|September 28, 2023
HBV DNA and HBsAg Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and HBsAg Loss in HBeAg-Negative Patients Who Discontinued Antiviral TherapyMilan J Sonneveld, Shao-Ming Chiu, Jun Yong Park, et al.
Journal of Hepatology|September 21, 2023
PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis BHo Soo Chun, George V Papatheodoridis, Minjong Lee, et al.
JHEP Reports : Innovation in Hepatology|May 1, 2026
Clinical features and management for CDK4/6 inhibitor-DILIMar Riveiro-Barciela, Paula Esteban, Kreina Sharela Vega-Cano, et al.
Journal of Viral Hepatitis|January 5, 2023
Clinical and patient-reported outcome profile of patients with hepatitis B viral infection from the Global Liver Registry™Zobair M Younossi, Ming-Lung Yu, Yusuf Yilmaz, et al.
Anti-Cancer Drugs|May 31, 2018
The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinomaRoberto Iacovelli, Maria Cossu Rocca, Luca Galli, et al.
Pageof 110

Showing results (951-960 of 1,095) with videos related to

Sort By:
Pageof 110
JHEP Reports : Innovation in Hepatology|July 24, 2023
Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: A multicentre cohort studyMilan J Sonneveld, Shao-Ming Chiu, Jun Yong Park, et al.
Journal of Hepatology|December 31, 2017
Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis CJavier Ampuero, Carlota Jimeno, Rosa Quiles, et al.
Cancer Immunology, Immunotherapy : CII|June 4, 2024
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinationsLorena Incorvaia, Fernando Sabino Marques Monteiro, Francesco Massari, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 10, 2011
A systematic review of hepatitis C virus epidemiology in Europe, Canada and IsraelMarkus Cornberg, Homie A Razavi, Alfredo Alberti, et al.
Clinical & Experimental Metastasis|November 21, 2025
Time to metastasis as a prognostic factor in metastatic urothelial carcinoma: results from the ARON-2 studyRenate Pichler, Gerald Klinglmair, Kirstin Binz, et al.
Gastroenterology|September 28, 2023
HBV DNA and HBsAg Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and HBsAg Loss in HBeAg-Negative Patients Who Discontinued Antiviral TherapyMilan J Sonneveld, Shao-Ming Chiu, Jun Yong Park, et al.
Journal of Hepatology|September 21, 2023
PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis BHo Soo Chun, George V Papatheodoridis, Minjong Lee, et al.
JHEP Reports : Innovation in Hepatology|May 1, 2026
Clinical features and management for CDK4/6 inhibitor-DILIMar Riveiro-Barciela, Paula Esteban, Kreina Sharela Vega-Cano, et al.
Journal of Viral Hepatitis|January 5, 2023
Clinical and patient-reported outcome profile of patients with hepatitis B viral infection from the Global Liver Registry™Zobair M Younossi, Ming-Lung Yu, Yusuf Yilmaz, et al.
Anti-Cancer Drugs|May 31, 2018
The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinomaRoberto Iacovelli, Maria Cossu Rocca, Luca Galli, et al.
Pageof 110